Medico Remedies Ltd Upgraded to Hold on Improved Technicals and Financial Metrics

Technical Trends Show Signs of Stabilisation

The primary catalyst for the upgrade stems from a shift in the technical grade from bearish to mildly bearish. While the stock’s daily moving averages remain bearish, weekly technical indicators have shown encouraging signs. The Moving Average Convergence Divergence (MACD) on a weekly basis has turned mildly bullish, suggesting a potential momentum shift. However, the monthly MACD remains bearish, indicating that longer-term trends are yet to fully confirm a turnaround.

Other technical signals present a mixed picture. The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no definitive signal, reflecting a neutral momentum. Bollinger Bands remain mildly bearish on weekly and monthly timeframes, implying some volatility and downward pressure. The Know Sure Thing (KST) indicator is bullish on a weekly basis but bearish monthly, reinforcing the notion of short-term optimism tempered by longer-term caution.

Volume-based indicators such as On-Balance Volume (OBV) are mildly bearish weekly, with no clear monthly trend. Dow Theory assessments also suggest a mildly bearish weekly trend and no clear monthly trend. Collectively, these technical nuances justify the upgrade to Hold, as the stock appears to be stabilising after a prolonged bearish phase but has not yet demonstrated a robust bullish reversal.

Valuation Remains Fair and Discounted Relative to Peers

Medico Remedies currently trades at ₹40.43, up 2.74% on the day, with a 52-week range between ₹31.00 and ₹56.99. Despite recent gains, the stock remains attractively valued compared to its pharmaceutical peers. The company’s Enterprise Value to Capital Employed ratio stands at a reasonable 4.4, reflecting a fair valuation given its operational scale and capital structure.

Its Price/Earnings to Growth (PEG) ratio of 0.8 further indicates undervaluation relative to its earnings growth potential. Over the past year, the stock has generated a modest return of -0.47%, underperforming the Sensex’s -7.08% return, yet its profits have risen by a robust 30%. This divergence suggests that the market has yet to fully price in the company’s improving fundamentals, supporting the Hold rating.

Financial Trend Strengthens with Consistent Quarterly Performance

Financially, Medico Remedies has demonstrated positive momentum, particularly in the latest quarter (Q4 FY25-26). Net sales surged by 37.55% to ₹56.81 crores, while Profit Before Depreciation, Interest and Taxes (PBDIT) reached a record ₹7.15 crores. Profit Before Tax excluding other income (PBT less OI) also hit a high of ₹5.45 crores, underscoring operational efficiency.

The company has reported positive results for five consecutive quarters, signalling sustained growth. Its Return on Capital Employed (ROCE) stands at a commendable 15.04%, reflecting high management efficiency in deploying capital. Additionally, the low Debt to EBITDA ratio of 0.82 times highlights a strong ability to service debt, reducing financial risk.

However, long-term growth remains a concern, with net sales growing at an annualised rate of only 14.28% over the past five years. This slower pace tempers enthusiasm but is offset by recent quarterly improvements and operational discipline.

Quality Assessment Reflects Stable Fundamentals Amid Micro-Cap Risks

Medico Remedies holds a Mojo Score of 52.0 and a Mojo Grade of Hold, upgraded from Sell on 2 July 2026. The company is classified as a micro-cap, which inherently carries higher volatility and risk. Despite this, the quality of management and financial discipline are evident in the consistent quarterly results and prudent capital management.

Promoters remain the majority shareholders, providing stability in ownership. The company’s ability to maintain profitability and service debt effectively supports the Hold rating, though investors should remain cautious given the stock’s historical underperformance relative to the broader market and sector benchmarks.

Comparative Returns Highlight Volatility and Long-Term Potential

Examining returns relative to the Sensex reveals a mixed performance. Over one week, Medico Remedies gained 0.22% versus the Sensex’s 0.52%. However, over one month and year-to-date periods, the stock underperformed significantly, with returns of -14.97% and -20.04% respectively, compared to Sensex gains of 3.82% and -9.06%. Over three years, the stock’s return was -46.96%, starkly contrasting with the Sensex’s 19.75% gain.

Despite this, the five-year return of 405.38% far outpaces the Sensex’s 47.67%, indicating that the company has delivered substantial long-term value for patient investors. This volatility underscores the micro-cap nature of the stock and the importance of monitoring technical and fundamental signals closely.

Outlook and Investment Considerations

Medico Remedies’ upgrade to Hold reflects a cautious optimism driven by improved technical indicators, fair valuation, and positive financial trends. Investors should note the stock’s mixed technical signals, with short-term bullishness offset by longer-term bearishness, and the company’s moderate long-term growth trajectory.

The company’s strong management efficiency, low leverage, and consistent quarterly performance provide a solid foundation. However, the micro-cap status and historical underperformance relative to benchmarks warrant a measured approach. The Hold rating suggests that investors may consider accumulating the stock selectively while awaiting clearer signs of sustained technical and fundamental improvement.

Summary of Ratings and Scores

• Mojo Score: 52.0 (Hold, upgraded from Sell)
• Market Cap Grade: Micro-cap
• ROCE: 15.04%
• Debt to EBITDA: 0.82 times
• PEG Ratio: 0.8
• Technical Grade: Mildly Bearish (upgraded from Bearish)
• Recent Quarterly Sales Growth: 37.55%
• Profit Growth (Last Year): 30%

Overall, Medico Remedies Ltd presents a balanced risk-reward profile with improving technicals and solid financial metrics, justifying the recent upgrade to Hold by MarketsMOJO analysts.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →